Search
Close this search box.
Search
Close this search box.

ASEAN

Disposable Vaping Devices Wreak Havoc On Our Global Ecosystem

Pure Labs Urges Government Entities to Put an End to This Major Source of Environmental Pollution & Youth Vaping Disposable Vape Waste TAMPA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) — Not only are disposable vaping devices fueling the world’s ongoing youth vaping epidemic, these single-use plastic e-cigarettes are responsible for

Elo Partners with FreedomPay to Transform the Digital In-Store Experience

PHILADELPHIA, Jan. 16, 2023 (GLOBE NEWSWIRE) — FreedomPay, the global leader in Next Level Commerce™, and Elo, a leading global provider of interactive solutions and interactive display solutions, announce the integration of Elo’s M60 Pay handheld computer with FreedomPay’s secure commerce technology. Built to accept today’s popular payment and loyalty

FreedomPay to Unleash the Power of Pay at NRF 2023

One of the world’s fastest growing fintech to showcase award-winning global commerce technology platform and industry-leading partner network. NEW YORK, National Retail Federation, Jan. 15, 2023 (GLOBE NEWSWIRE) — FreedomPay, the global leader in Next Level Commerce™ and the commerce technology platform of choice for global retail, hospitality and payments

Flooid Announces Strategic Partnership with FreedomPay to Expand Global Reach

The partnership will bring enhanced commerce functionality to Retailers around the world. London, England, Jan. 13, 2023 (GLOBE NEWSWIRE) — Flooid today announces a strategic partnership with FreedomPay, the global leader in Next Level Commerce™, to bring industry-leading Retail solutions to merchants globally. Powered by FreedomPay, Flooid allows merchants to

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan.

RECENT NEWS

Copyright © 2024 Pakistan Press Release Point. All rights reserved.